|
US4476116A
(en)
|
1982-12-10 |
1984-10-09 |
Syntex (U.S.A.) Inc. |
Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
AU5698186A
(en)
|
1985-03-15 |
1986-10-13 |
Summerton, J. |
Polynucleotide assay reagent and method
|
|
US4866042A
(en)
|
1987-11-18 |
1989-09-12 |
Neuwelt Edward A |
Method for the delivery of genetic material across the blood brain barrier
|
|
US6294520B1
(en)
|
1989-03-27 |
2001-09-25 |
Albert T. Naito |
Material for passage through the blood-brain barrier
|
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
|
US7101993B1
(en)
|
1990-01-11 |
2006-09-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides containing 2′-O-modified purines
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
DE69133511T2
(de)
|
1990-08-13 |
2006-09-28 |
Isis Pharmaceuticals, Inc., Carlsbad |
Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
DE69333842T2
(de)
|
1992-07-23 |
2006-04-27 |
Isis Pharmaceuticals, Inc., Carlsbad |
Neue 2'-O-Alkyl-Nukleoside und -Phosphoramidite, Verfahren zu ihrer Herstellung und ihre Verwendungen
|
|
AU692423B2
(en)
|
1992-09-25 |
1998-06-11 |
Institut National De La Sante Et De La Recherche Medicale |
Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
|
|
EP0698092B1
(en)
|
1993-05-11 |
2007-07-25 |
The University Of North Carolina At Chapel Hill |
Antisense oligonucleotides which combat aberrant splicing and methods of using the same
|
|
EP0736094A1
(en)
|
1993-12-24 |
1996-10-09 |
Medical Research Council |
Polycystic kidney disease 1 gene and uses thereof
|
|
US5656612A
(en)
|
1994-05-31 |
1997-08-12 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
|
FR2727867B1
(fr)
|
1994-12-13 |
1997-01-31 |
Rhone Poulenc Rorer Sa |
Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
|
|
US6166197A
(en)
|
1995-03-06 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
|
|
CA2246229C
(en)
|
1996-02-14 |
2011-08-23 |
Isis Pharmaceuticals Inc. |
Sugar-modified gapped oligonucleotides
|
|
GB9605808D0
(en)
|
1996-03-20 |
1996-05-22 |
Isis Innovation |
CFTR gene regulator
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
|
ATE312935T1
(de)
|
1997-06-03 |
2005-12-15 |
|
Regulatorische sequenzen für die in-vivo- expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen.
|
|
US6963589B1
(en)
|
1997-07-03 |
2005-11-08 |
Canon Kabushiki Kaisha |
Information processing apparatus for and method of transmitting and/or receiving broadcast signal
|
|
US6391452B1
(en)
|
1997-07-18 |
2002-05-21 |
Bayer Corporation |
Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
|
|
GB9716231D0
(en)
|
1997-07-31 |
1997-10-08 |
Amersham Int Ltd |
Base analogues
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
JP4236812B2
(ja)
|
1997-09-12 |
2009-03-11 |
エクシコン エ／エス |
オリゴヌクレオチド類似体
|
|
US7045610B2
(en)
|
1998-04-03 |
2006-05-16 |
Epoch Biosciences, Inc. |
Modified oligonucleotides for mismatch discrimination
|
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
US7071324B2
(en)
|
1998-10-13 |
2006-07-04 |
Brown University Research Foundation |
Systems and methods for sequencing by hybridization
|
|
US20030224514A1
(en)
|
2002-05-31 |
2003-12-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of PPAR-delta expression
|
|
US6436657B1
(en)
|
1998-12-18 |
2002-08-20 |
E. I. Du Pont De Nemours And Company |
Polynucleotides encoding aminomethyltransferases
|
|
ATE287897T2
(de)
|
1999-02-12 |
2005-02-15 |
Sankyo Co |
Analoga von nukleosiden und oligonukleotiden
|
|
EP1161439B1
(en)
|
1999-03-18 |
2010-04-21 |
Exiqon A/S |
Xylo-lna analogues
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
|
AU3418800A
(en)
|
1999-03-24 |
2000-10-09 |
Exiqon A/S |
Improved synthesis of (2.2.1)bicyclo nucleosides
|
|
US6383752B1
(en)
|
1999-03-31 |
2002-05-07 |
Hybridon, Inc. |
Pseudo-cyclic oligonucleobases
|
|
CN102180924A
(zh)
|
1999-05-04 |
2011-09-14 |
桑塔里斯制药公司 |
L-核糖-lna类似物
|
|
US6083482A
(en)
|
1999-05-11 |
2000-07-04 |
Icn Pharmaceuticals, Inc. |
Conformationally locked nucleosides and oligonucleotides
|
|
US6531591B1
(en)
|
1999-07-07 |
2003-03-11 |
Exiqon A/S |
Synthesis of stable quinone and photoreactive ketone phosphoramidite reagents for solid phase synthesis of photoreactive-oligomer conjugates
|
|
JP4151751B2
(ja)
|
1999-07-22 |
2008-09-17 |
第一三共株式会社 |
新規ビシクロヌクレオシド類縁体
|
|
US6677445B1
(en)
|
1999-08-27 |
2004-01-13 |
Chiron Corporation |
Chimeric antisense oligonucleotides and cell transfecting formulations thereof
|
|
US6187586B1
(en)
|
1999-12-29 |
2001-02-13 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of AKT-3 expression
|
|
KR20020097241A
(ko)
|
2000-05-04 |
2002-12-31 |
에이브이아이 바이오파마 인코포레이티드 |
스플라이스-영역 안티센스 조성물 및 방법
|
|
US6809194B1
(en)
|
2000-05-10 |
2004-10-26 |
Chiron Corporation |
Akt3 inhibitors
|
|
CA2697031C
(en)
|
2000-07-13 |
2017-10-31 |
The Johns Hopkins University School Of Medicine |
Detection and treatment of polycystic kidney disease
|
|
AU2001282522A1
(en)
|
2000-08-29 |
2002-03-13 |
Takeshi Imanishi |
Novel nucleoside analogs and oligonucleotide derivatives containing these analogs
|
|
HUP0301805A3
(en)
|
2000-09-02 |
2005-12-28 |
Gruenenthal Gmbh |
Antisense oligonucleotides against vanilloid receptor 1
|
|
AU2001293687A1
(en)
|
2000-10-04 |
2002-04-15 |
Cureon A/S |
Improved synthesis of purine locked nucleic acid analogues
|
|
JP2002345489A
(ja)
|
2000-11-03 |
2002-12-03 |
Astrazeneca Ab |
化学物質
|
|
DK1409497T3
(da)
|
2001-07-12 |
2005-05-30 |
Santaris Pharma As |
Fremgangsmåde til fremstilling af LNA-phosphoramiditer
|
|
WO2003016492A2
(en)
|
2001-08-16 |
2003-02-27 |
The Regents Of The University Of Michigan |
Adamts13 genes and proteins and variants, and uses thereof
|
|
US7060809B2
(en)
|
2001-09-04 |
2006-06-13 |
Exiqon A/S |
LNA compositions and uses thereof
|
|
US6936589B2
(en)
|
2001-09-28 |
2005-08-30 |
Albert T. Naito |
Parenteral delivery systems
|
|
JP2005508196A
(ja)
|
2001-11-07 |
2005-03-31 |
アプレラ コーポレイション |
核酸分析の汎用ヌクレオチド
|
|
US7615619B2
(en)
|
2002-02-13 |
2009-11-10 |
Takeshi Imanishi |
Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof
|
|
AU2003222743B2
(en)
|
2002-05-08 |
2008-12-11 |
Roche Innovation Center Copenhagen A/S |
Synthesis of locked nucleic acid derivatives
|
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
|
WO2004001010A2
(en)
|
2002-06-21 |
2003-12-31 |
Ptc Therapeutics, Inc. |
METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
|
|
US20040023220A1
(en)
|
2002-07-23 |
2004-02-05 |
Lawrence Greenfield |
Integrated method for PCR cleanup and oligonucleotide removal
|
|
US20060058253A1
(en)
|
2002-08-12 |
2006-03-16 |
Benoit Chabot |
Methods to reprogram splice site selection in pre-messenger rnas
|
|
WO2004014222A2
(en)
|
2002-08-12 |
2004-02-19 |
The Regents Of The University Of Michigan |
Diagnosis and treatment of tuberous sclerosis
|
|
EP1562971B1
(en)
|
2002-11-05 |
2014-02-12 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
ATE442152T1
(de)
|
2002-11-18 |
2009-09-15 |
Santaris Pharma As |
Antisense-entwurf
|
|
US7217807B2
(en)
*
|
2002-11-26 |
2007-05-15 |
Rosetta Genomics Ltd |
Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
|
|
ATE479752T1
(de)
|
2003-03-07 |
2010-09-15 |
Alnylam Pharmaceuticals Inc |
Therapeutische zusammensetzungen
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
EP2141234B1
(en)
|
2003-03-21 |
2016-04-27 |
Roche Innovation Center Copenhagen A/S |
Short Interfering RNA (siRNA) Analogues
|
|
KR20060015505A
(ko)
|
2003-04-13 |
2006-02-17 |
엔존 파마슈티컬즈, 인코포레이티드 |
올리고뉴클레오타이드 전구약물
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
US20070009899A1
(en)
*
|
2003-10-02 |
2007-01-11 |
Mounts William M |
Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
|
|
GB0326578D0
(en)
|
2003-11-14 |
2003-12-17 |
Univ Belfast |
Cancer diagnosis and therapy
|
|
US20050221354A1
(en)
|
2004-02-18 |
2005-10-06 |
Wyeth |
Nucleic acid arrays for monitoring expression profiles of drug target genes
|
|
WO2005111211A2
(en)
|
2004-05-14 |
2005-11-24 |
Rosetta Genomics Ltd. |
Micronas and uses thereof
|
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
US20070087376A1
(en)
|
2004-08-30 |
2007-04-19 |
Potashkin Judith A |
Splice variants of pre-mRNA transcripts as biomarkers in idiopathic neurodegenerative diseases
|
|
EP1812798A2
(en)
|
2004-11-19 |
2007-08-01 |
Acadia Pharmaceuticals Inc. |
Enabling tools to identify ligands for hormone nuclear receptors
|
|
WO2006081311A2
(en)
|
2005-01-26 |
2006-08-03 |
Medical College Of Georgia Research Institute |
Compositions and methods for the intracellular disruption of vegf and vegfr-2 by intraceptors
|
|
US20100150839A1
(en)
|
2005-02-04 |
2010-06-17 |
Massachusetts Institute Of Technology |
Compositions and Methods for Modulating Cognitive Function
|
|
WO2006107846A2
(en)
|
2005-04-01 |
2006-10-12 |
University Of Florida Research Foundation, Inc. |
Biomakers of liver injury
|
|
US7557198B2
(en)
*
|
2005-05-04 |
2009-07-07 |
Exagen Diagnostics, Inc. |
Acute myelogenous leukemia biomarkers
|
|
AU2006257073B2
(en)
|
2005-06-17 |
2011-08-04 |
Children's Medical Center Corporation |
ADAMTS13-comprising compositions having thrombolytic activity
|
|
PT3308788T
(pt)
|
2005-06-23 |
2019-01-30 |
Cold Spring Harbor Laboratory |
Composições e métodos para a modulação do splicing de smn2
|
|
EP4174179B1
(en)
|
2005-08-23 |
2025-05-07 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
|
WO2007028065A2
(en)
|
2005-08-30 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
|
US8258109B2
(en)
|
2005-10-20 |
2012-09-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of LMNA expression
|
|
US20080280848A1
(en)
|
2005-10-28 |
2008-11-13 |
Volker Patzel |
Structures of Active Guide Rna Molecules and Method of Selection
|
|
WO2007048629A2
(en)
|
2005-10-28 |
2007-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modulation of rna silencing efficiency by argonaute proteins
|
|
EP1954254A4
(en)
|
2005-11-01 |
2010-12-22 |
Harvard College |
MODULATION OF THE LOADING OF THE ENDOPLASMIC RETICULUM IN THE TREATMENT OF TUBEROUS SCLEROSIS
|
|
US7785834B2
(en)
|
2005-11-10 |
2010-08-31 |
Ercole Biotech, Inc. |
Soluble TNF receptors and their use in treatment of disease
|
|
EP1792981A1
(en)
|
2005-12-02 |
2007-06-06 |
Humboldt-Universität zu Berlin |
Microginin producing proteins and nucleic acids encoding a microginin gene cluster as well as methods for creating microginins
|
|
PT2161038E
(pt)
|
2006-01-26 |
2014-03-10 |
Isis Pharmaceuticals Inc |
Composições e suas utilizações dirigidas à huntingtina
|
|
CN102908630B
(zh)
|
2006-01-27 |
2014-11-19 |
Isis制药公司 |
6-修饰的双环核酸类似物
|
|
EP1984499B1
(en)
|
2006-01-27 |
2015-05-27 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of micrornas
|
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
|
US8007790B2
(en)
|
2006-04-03 |
2011-08-30 |
Stowers Institute For Medical Research |
Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
|
|
EP2015758B1
(en)
|
2006-05-05 |
2014-04-02 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression apob
|
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
EP2066684B1
(en)
|
2006-05-11 |
2012-07-18 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
CN101460624B
(zh)
|
2006-06-08 |
2013-06-05 |
阿明诺化学株式会社 |
具有iNOS的表达控制作用的正义寡核苷酸以及含有其的组合物
|
|
WO2008001778A1
(fr)
|
2006-06-27 |
2008-01-03 |
Takeda Pharmaceutical Company Limited |
Animal génétiquement modifié et son utilisation
|
|
CA2658421C
(en)
|
2006-07-24 |
2018-03-20 |
Athena Diagnostics, Inc. |
Pkd mutations and evaluation of same
|
|
ES2620472T5
(es)
|
2006-10-18 |
2020-07-09 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
|
US20090264353A1
(en)
|
2007-10-19 |
2009-10-22 |
Santaris Pharma A/S |
Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
|
|
DK2099461T3
(da)
|
2006-11-13 |
2012-07-02 |
Santaris Pharma As |
LNA Nukleoside Phosphoramidates
|
|
US8293684B2
(en)
|
2006-11-29 |
2012-10-23 |
Exiqon |
Locked nucleic acid reagents for labelling nucleic acids
|
|
EP2118118B1
(en)
|
2007-01-19 |
2017-09-27 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
|
US20100093836A1
(en)
|
2007-01-29 |
2010-04-15 |
Isis Pharmaceuticals, Inc |
Compounds and methods for modulating protein expression
|
|
WO2008111485A1
(ja)
|
2007-03-09 |
2008-09-18 |
Riken |
モノヌクレオシドまたはモノヌクレオチドから誘導される構造を有する化合物、核酸、標識物質、核酸検出方法およびキット
|
|
AR065648A1
(es)
|
2007-03-09 |
2009-06-24 |
Pioneer Hi Bred Int |
Identificacion de transportadores de amonio (amts) para la regulacion del metabolismo de nitrogeno en plantas
|
|
WO2008111908A1
(en)
|
2007-03-15 |
2008-09-18 |
Jyoti Chattopadhyaya |
Five- and six-membered conformationally locked 2',4'- carbocyclic ribo-thymidines for the treatment of infections and cancer
|
|
EP2149605B1
(en)
|
2007-03-22 |
2013-07-03 |
Santaris Pharma A/S |
Short RNA antagonist compounds for the modulation of target mRNA
|
|
ES2388590T3
(es)
|
2007-05-30 |
2012-10-16 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido.
|
|
WO2008154401A2
(en)
|
2007-06-08 |
2008-12-18 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
|
WO2009006478A2
(en)
|
2007-07-05 |
2009-01-08 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
|
KR101654007B1
(ko)
|
2007-08-15 |
2016-09-05 |
아이오니스 파마수티컬즈, 인코포레이티드 |
테트라하이드로피란 핵산 유사체
|
|
ES2639852T3
(es)
|
2007-10-26 |
2017-10-30 |
Academisch Ziekenhuis Leiden |
Medios y métodos para contrarrestar los trastornos musculares
|
|
WO2009064920A2
(en)
|
2007-11-13 |
2009-05-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
|
WO2009067647A1
(en)
|
2007-11-21 |
2009-05-28 |
Isis Pharmaceuticals, Inc. |
Carbocyclic alpha-l-bicyclic nucleic acid analogs
|
|
CA2910760C
(en)
|
2007-12-04 |
2019-07-09 |
Muthiah Manoharan |
Targeting lipids
|
|
US8846386B2
(en)
|
2007-12-18 |
2014-09-30 |
University Of Kentucky Research Foundation |
sVEGFR-2 and its role in lymphangiogenesis modulation
|
|
JP5608863B2
(ja)
|
2007-12-28 |
2014-10-15 |
公立大学法人横浜市立大学 |
新生児期〜乳児期発症の難治性てんかんの検出方法
|
|
WO2009099942A2
(en)
|
2008-01-31 |
2009-08-13 |
Alnylam Pharmaceuticals, Inc. |
Chemically modified oligonucleotides and uses thereof
|
|
US8530640B2
(en)
|
2008-02-07 |
2013-09-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
|
EP2276855B1
(en)
|
2008-03-13 |
2016-05-11 |
Celera Corporation |
Genetic polymorphisms associated wiith venous thrombosis, methods of detection and uses thereof
|
|
EP2274423A2
(en)
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
DK2285819T3
(da)
|
2008-04-04 |
2013-12-02 |
Isis Pharmaceuticals Inc |
Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
|
|
EP2119783A1
(en)
*
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US8710021B2
(en)
|
2008-06-11 |
2014-04-29 |
Bionucleon S.R.L. |
Inhibition of HRP-3 using modified oligonucleotides
|
|
EP2151248A1
(en)
|
2008-07-30 |
2010-02-10 |
Johann Bauer |
Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
US8501805B2
(en)
|
2008-09-24 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-L-bicyclic nucleosides
|
|
WO2010051632A1
(en)
|
2008-11-07 |
2010-05-14 |
Centre Hospitalier Universitaire Sainte-Justine |
Syngap1 dysfunctions and uses thereof in diagnostic and therapeutic applications for mental retardation
|
|
EP2370581B1
(en)
|
2008-12-04 |
2016-08-03 |
CuRNA, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
|
US9006194B2
(en)
|
2008-12-19 |
2015-04-14 |
Drexel University |
Compositions and methods for diminishing viral infection and inflammation associated with viral infection
|
|
US20100166784A1
(en)
*
|
2008-12-30 |
2010-07-01 |
The Washington University |
Method and compositions for modulating th17 cell development
|
|
US8680254B2
(en)
|
2009-01-14 |
2014-03-25 |
Philadelphia Health & Education Corporation |
Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
|
|
CN102459597B
(zh)
|
2009-05-08 |
2020-06-30 |
库尔纳公司 |
通过针对dmd家族的天然反义转录物的抑制治疗肌营养蛋白家族相关疾病
|
|
AU2010262862C1
(en)
|
2009-06-17 |
2020-04-30 |
Biogen Ma Inc. |
Compositions and methods for modulation of SMN2 splicing in a subject
|
|
EP2275545A1
(en)
|
2009-07-16 |
2011-01-19 |
Julius-Maximilians-Universität Würzburg |
Use of microRNA-24 and/or its targets for the treatment and prevention of ischemia and induction of angiogenesis
|
|
EP2462153B1
(en)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
|
WO2011020118A1
(en)
|
2009-08-14 |
2011-02-17 |
Theramind Research, Llc |
Methods and compositions for treatment of tuberous sclerosis complex
|
|
EP3135772B1
(en)
|
2009-09-08 |
2019-10-23 |
Laboratory Corporation of America Holdings |
Method for diagnosing autism spectrum disorders
|
|
WO2011032034A2
(en)
|
2009-09-10 |
2011-03-17 |
University Of Idaho |
Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids
|
|
JPWO2011052436A1
(ja)
|
2009-10-29 |
2013-03-21 |
国立大学法人大阪大学 |
架橋型人工ヌクレオシドおよびヌクレオチド
|
|
PL2499249T3
(pl)
*
|
2009-11-12 |
2019-03-29 |
Univ Western Australia |
Cząsteczki antysensowne i sposoby leczenia patologii
|
|
US9334495B2
(en)
|
2009-11-25 |
2016-05-10 |
Elitechgroup B.V. |
Minor groove binder (MGB)-oligonucleotide miRNA antagonists
|
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP3321361B1
(en)
|
2010-02-08 |
2019-03-27 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP2550361B1
(en)
|
2010-03-25 |
2017-02-08 |
The J. David Gladstone Institutes |
Compositions and methods for treating neurological disorders
|
|
WO2011127210A1
(en)
|
2010-04-06 |
2011-10-13 |
Massachusetts Institute Of Technology |
Targeted delivery of nucleic acids
|
|
US20110269735A1
(en)
|
2010-04-19 |
2011-11-03 |
Celera Corporation |
Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
|
|
KR20130103662A
(ko)
|
2010-04-19 |
2013-09-24 |
엔라이프 떼라퓨틱스, 에스.엘. |
올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
|
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
|
EP2606057B1
(en)
|
2010-04-28 |
2016-06-15 |
Ionis Pharmaceuticals, Inc. |
Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
|
|
CA2799944A1
(en)
|
2010-05-20 |
2011-11-24 |
University Of Rochester |
Methods and compositions related to modulating autophagy
|
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
WO2011156202A1
(en)
|
2010-06-08 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
US9518259B2
(en)
|
2010-06-15 |
2016-12-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating interaction between proteins and target nucleic acids
|
|
PL2585596T3
(pl)
|
2010-06-23 |
2021-06-28 |
Curna, Inc. |
Leczenie chorób związanych z podjednostką alfa kanału sodowego bramkowanego napięciem (SCNA) poprzez hamowanie naturalnego transkryptu antysensownego SCNA
|
|
WO2012054723A2
(en)
|
2010-10-22 |
2012-04-26 |
Opko Curna Llc |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
|
WO2012106529A1
(en)
|
2011-02-02 |
2012-08-09 |
The Trustees Of Princeton University |
Jagged1 as a marker and therapeutic target for breast cancer bone metastasis
|
|
WO2012138487A2
(en)
|
2011-04-07 |
2012-10-11 |
The Board Of Regents Of The University Of Texas System |
Oligonucleotide modulation of splicing
|
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US9957558B2
(en)
|
2011-04-28 |
2018-05-01 |
Life Technologies Corporation |
Methods and compositions for multiplex PCR
|
|
US20140357558A1
(en)
|
2011-06-24 |
2014-12-04 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of spinal muscular atrophy
|
|
US9605019B2
(en)
|
2011-07-19 |
2017-03-28 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
US8592156B2
(en)
|
2011-08-08 |
2013-11-26 |
Roche Molecular Systems, Inc. |
Predicting response to anti-CD20 therapy in DLBCL patients
|
|
EP3640332A1
(en)
|
2011-08-29 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
WO2013036403A1
(en)
|
2011-09-06 |
2013-03-14 |
Curna, Inc. |
TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
|
|
US9453261B2
(en)
|
2011-09-20 |
2016-09-27 |
The George Washington University |
Alternative splicing variants of genes associated with prostate cancer risk and survival
|
|
BR112014011018A2
(pt)
|
2011-11-11 |
2017-05-02 |
Santaris Pharma As |
compostos para modulação de splining de smn2
|
|
US9534222B2
(en)
|
2011-11-15 |
2017-01-03 |
University Of Utah Research Foundation |
Morpholinos, morpholino upregulating, and associated methods
|
|
CN104053786B
(zh)
|
2011-11-29 |
2017-06-06 |
生命技术公司 |
用于多重pcr的方法和组合物
|
|
US20150025231A1
(en)
|
2012-01-11 |
2015-01-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for modulation of ikbkap splicing
|
|
EP2812342B1
(en)
|
2012-02-08 |
2017-11-15 |
Ionis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
|
BR112014019750B1
(pt)
|
2012-02-10 |
2020-03-03 |
F. Hoffmann-La Roche Ag. |
Composto, composição farmacêutica e seus usos
|
|
US8846885B2
(en)
|
2012-02-17 |
2014-09-30 |
Ajinomoto Co., Inc. |
Oligonucleotide with protected base
|
|
US9221864B2
(en)
|
2012-04-09 |
2015-12-29 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US20140378526A1
(en)
|
2012-05-11 |
2014-12-25 |
City Of Hope |
Design of nucleic acid binding molecules with non-watson crick and non-canonical pairing based on artificial mutation consensus sequences to counter escape mutations
|
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
SG10201912895PA
(en)
|
2012-07-13 |
2020-02-27 |
Wave Life Sciences Ltd |
Chiral control
|
|
US8729263B2
(en)
|
2012-08-13 |
2014-05-20 |
Novartis Ag |
1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
|
|
CA2880869A1
(en)
|
2012-08-20 |
2014-02-27 |
The Regents Of The University Of California |
Polynucleotides having bioreversible groups
|
|
EP2898072A1
(en)
|
2012-09-24 |
2015-07-29 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Restoration of the cftr function by splicing modulation
|
|
WO2014049536A2
(en)
|
2012-09-25 |
2014-04-03 |
Universidade De Lisboa |
Drug targets for cystic fibrosis and other conditions
|
|
US9192621B2
(en)
|
2012-09-27 |
2015-11-24 |
Idenix Pharmaceuticals Llc |
Esters and malonates of SATE prodrugs
|
|
UA116639C2
(uk)
|
2012-10-09 |
2018-04-25 |
Рег'Юлес Терап'Ютікс Інк. |
Способи лікування синдрому альпорта
|
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
US20150291957A1
(en)
|
2012-10-26 |
2015-10-15 |
Larry J. Smith |
METHODS AND COMPOSITIONS TO PRODUCE ss-RNAi ACTIVITY WITH ENHANCED POTENCY
|
|
US9909128B2
(en)
|
2012-11-15 |
2018-03-06 |
The Regents Of The University Of California |
Splice modulating oligonucleotides that inhibit cancer
|
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
CN104004826B
(zh)
|
2013-01-07 |
2016-03-02 |
赵晨 |
突变的基因prpf4在制备遗传性视网膜疾病诊断试剂中的应用
|
|
US20150361497A1
(en)
|
2013-01-18 |
2015-12-17 |
Anna Mary ROSE |
Therapeutics and diagnostics based on minisatellite repeat element 1 (msr1)
|
|
EP3778618A1
(en)
|
2013-02-04 |
2021-02-17 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
WO2014126229A1
(ja)
|
2013-02-18 |
2014-08-21 |
塩野義製薬株式会社 |
含窒素複素環構造を有するヌクレオシド及びヌクレオチド
|
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
US10590412B2
(en)
|
2013-04-19 |
2020-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
|
KR102138781B1
(ko)
|
2013-05-01 |
2020-07-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포지질단백질 c-iii 발현을 조절하는 조성물 및 방법
|
|
WO2014198890A1
(en)
|
2013-06-13 |
2014-12-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
|
|
WO2014201413A1
(en)
|
2013-06-14 |
2014-12-18 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating non-coding rna
|
|
WO2014209841A2
(en)
|
2013-06-25 |
2014-12-31 |
F. Hoffmann-La Roche Ag |
Compounds for treating spinal muscular atrophy
|
|
AU2014306416B2
(en)
|
2013-08-16 |
2021-02-25 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating RNA
|
|
WO2015023941A1
(en)
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Oligonucleotides targeting euchromatin regions of genes
|
|
EP3033423A4
(en)
|
2013-08-16 |
2017-04-26 |
Rana Therapeutics Inc. |
Epigenetic regulators of frataxin
|
|
WO2015023939A1
(en)
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin
|
|
KR20160045063A
(ko)
|
2013-08-19 |
2016-04-26 |
에프. 호프만-라 로슈 아게 |
스크리닝 방법
|
|
PL3041958T3
(pl)
|
2013-09-04 |
2020-11-02 |
Cold Spring Harbor Laboratory |
Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi
|
|
WO2015035231A1
(en)
|
2013-09-05 |
2015-03-12 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
|
EP3480312A1
(en)
|
2013-09-11 |
2019-05-08 |
Synthena AG |
Nucleic acids and methods for the treatment of pompe disease
|
|
AU2015272128B2
(en)
|
2014-06-10 |
2021-10-28 |
Erasmus University Medical Center Rotterdam |
Antisense oligonucleotides useful in treatment of Pompe disease
|
|
GB201410693D0
(en)
*
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
GB201411468D0
(en)
|
2014-06-27 |
2014-08-13 |
Univ Edinburgh |
Novel treatment for endometriosis
|
|
GB2547586A
(en)
|
2014-08-20 |
2017-08-23 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof(In the PCT request)
|
|
KR102620328B1
(ko)
|
2014-10-03 |
2024-01-02 |
콜드스프링하버러보러토리 |
핵 유전자 산출량의 표적화 증강
|
|
EP3207048A4
(en)
|
2014-10-17 |
2018-05-30 |
The Broad Institute, Inc. |
Compositions and methods of treating muscular dystrophy
|
|
WO2016077837A1
(en)
|
2014-11-14 |
2016-05-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of proteins
|
|
GB201421379D0
(en)
|
2014-12-02 |
2015-01-14 |
Isis Innovation Ltd And Medical Res Council |
Molecule
|
|
CN114642735A
(zh)
|
2015-01-21 |
2022-06-21 |
菲泽尔克斯公司 |
用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
|
|
JP6884102B2
(ja)
|
2015-02-09 |
2021-06-09 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための化合物
|
|
US9840709B2
(en)
|
2015-02-20 |
2017-12-12 |
Rosalind Franklin University Of Medicine And Science |
Antisense compounds targeting genes associated with cystic fibrosis
|
|
EP3262056A4
(en)
|
2015-02-27 |
2018-09-19 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
|
HK1249140A1
(zh)
|
2015-04-03 |
2018-10-26 |
Ionis Pharmaceuticals, Inc. |
用於调节tmprss6表达的化合物和方法
|
|
EP4249472A3
(en)
|
2015-05-30 |
2023-12-13 |
PTC Therapeutics, Inc. |
Methods for modulating rna splicing
|
|
EP3352872A4
(en)
|
2015-09-24 |
2019-07-10 |
The Trustees of the University of Pennsylvania |
TRIPTYENE DERIVATIVES FOR STABILIZING A NUCLEIC ACID COMPOUND
|
|
GB2546719B
(en)
|
2015-10-09 |
2021-07-14 |
Univ Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
|
KR20220105174A
(ko)
|
2015-10-09 |
2022-07-26 |
유니버시티 오브 사우스앰톤 |
유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
|
|
EP3183347A4
(en)
|
2015-10-17 |
2018-04-18 |
Lifesplice Pharma LLC |
Splice modulating oligonucleotides and methods of use thereof
|
|
CA3005090A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of liver diseases
|
|
CA3005247A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of polycystic kidney disease
|
|
CA3005246A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of central nervous system diseases
|
|
CA3005131A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of tuberous sclerosis complex
|
|
WO2017106292A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of kidney diseases
|
|
WO2017106370A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of eye diseases
|
|
ES2903394T3
(es)
|
2015-12-14 |
2022-04-01 |
Cold Spring Harbor Laboratory |
Composiciones para el tratamiento de la retinitis pigmentosa 13
|
|
CN109312343B
(zh)
|
2015-12-14 |
2022-09-27 |
冷泉港实验室 |
用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
|
|
EP3389671A4
(en)
|
2015-12-14 |
2019-07-17 |
Cold Spring Harbor Laboratory |
ANTISENSE OLIGOMERS FOR THE TREATMENT OF ALAGILLE SYNDROME
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
CN117821509A
(zh)
|
2017-04-03 |
2024-04-05 |
编码治疗公司 |
组织选择性转基因表达
|
|
SMT202400071T1
(it)
|
2017-08-25 |
2024-03-13 |
Stoke Therapeutics Inc |
Oligomeri antisenso per il trattamento di condizioni e malattie
|
|
DK3700570T3
(da)
|
2017-10-23 |
2025-03-31 |
Stoke Therapeutics Inc |
Antisense-oligomerer til behandling af ikke-sense medieret rna henfald baserede tilstande og sygdomme
|